Inovio (INO) Pharmaceuticals announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of its common stock, in an underwritten public offering ...

Inovio’s upside hinges on INO-3107 for HPV-6/11 RRP with FDA PDUFA Oct 2026, regulatory risk, tight cash, and cheap EV. Check ...

This was the stock's third consecutive day of losses.

Inovio is on track for filing its BLA for INO-3107 in the latter half of 2024. INO-3107 has little in the way of pipeline support. Expect significant dilution as Inovio proceeds with its BLA and ...

A quick analysis of Inovio Pharmaceuticals' (NASDAQ: INO) stock performance history shows plenty of twists and turns -- from the company's early biomedical days to its recent advances in developing a ...

Investors might want to bet on Inovio Pharmaceuticals (INO), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings ...

The stock's fall snapped a two-day winning streak.